Gilead's new drug keeps 56 percent of lymphoma trial patients alive - Reuters

Medical Xpress

Gilead's new drug keeps 56 percent of lymphoma trial patients alive Reuters (Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday ... CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaPR Newswire (press release) Phase 2 CAR-T study reports significant remission rates at 15-month follow upEurekAlert (press release) Global CAR T therapy trial shows high rates of durable remission for NHLMedical Xpress Markets Insider -Financial Times all 9 news articles »

from Health - Google News http://ift.tt/2jliYoo